Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11635929 | 0.85 | CYP19A1 (0.53) | CYP19A1MAOBSIGMAR1PKMTSHR | |
| SCHEMBL15603238 | 0.83 | CYP19A1 (0.47) | CYP19A1MAOBSIGMAR1PKMTSHR | |
| Fluoride SCHEMBL11424190 | 0.82 | CYP19A1 (0.50) | CYP19A1MAOBSIGMAR1PKMTSHR | |
| SCHEMBL8470409 | 0.81 | CYP19A1 (0.49) | CYP19A1MAOBSIGMAR1PKMTSHR | |
| SCHEMBL11638586 | 0.81 | MAOB (0.49) | CYP19A1MAOBSIGMAR1TSHRHTR1A | |
| SCHEMBL11424192 | 0.80 | CYP19A1 (0.48) | CYP19A1MAOBSIGMAR1PKMTSHR | |
| SCHEMBL9832882 | 0.79 | MAOB (0.47) | CYP19A1MAOBSIGMAR1HTR1A | |
| SCHEMBL1990181 | 0.77 | ALDH1A1 (0.50) | CYP19A1MAOB | |
| SCHEMBL7840882 | 0.77 | CYP19A1 (0.46) | CYP19A1MAOBSIGMAR1PKMTSHR | |
| SCHEMBL2794624 | 0.77 | GLS (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-20220011665-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1499306-A4 | BICYCLIC AMIDES | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20050203112-A1 | Bicyclic amides | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
| EP-1499306-A2 | BICYCLIC AMIDES | Merck & Co., Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003086288-A2 | BICYCLIC AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220011665-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT | MRPS23, MRPS22, SLC11A2 | CYP19A1 3468/4885MAOB 4053/4885SIGMAR1 348/4885 |
| US-20050203112-A1 | Bicyclic amides | CNR1, CNR2, FAAH | CYP19A1 1296/4885MAOB 550/4885SIGMAR1 750/4885 |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | MRPS23, MRPS22, SLC11A2 | CYP19A1 3464/4885MAOB 4031/4885SIGMAR1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.